Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;83(1):131-143.
doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30.

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Ece Esin  1 , B Oksuzoglu  2 , A Bilici  3 , I Cicin  4 , O Kostek  4 , M A Kaplan  5 , S Aksoy  6 , B Y Aktas  6 , O Ozdemir  7 , A Alacacioglu  7 , D Cabuk  8 , A T Sumbul  9 , A Sakin  10 , S Paydas  11 , E Yetisir  11 , O Er  12 , T Korkmaz  13 , N Yildirim  14 , T Sakalar  15 , H Demir  16 , M Artac  17 , M Karaagac  17 , H Harputluoglu  18 , E Bilen  18 , E Erdur  2 , S Degirmencioglu  19 , A Aliyev  20 , T Cil  21 , P Olgun  21 , G Basaran  12 , O Gumusay  22 , A Demir  23 , E Tanrikulu  24 , P F Yumuk  24 , Inanc Imamoglu  25 , B Oyan  13 , B Cetin  26 , V Haksoyler  27 , N Karadurmus  28 , I Erturk  28 , T Evrensel  29 , H Yilmaz  29 , I Beypinar  30 , M Kocer  31 , K N Pilanci  32 , M Seker  33 , Y Urun  34 , N Yildirim  35 , T Eren  35 , U Demirci  2 ; Turkish Oncology Group
Collaborators, Affiliations

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Ece Esin et al. Cancer Chemother Pharmacol. 2019 Jan.

Abstract

Purpose: In this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.

Methods: This study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.

Results: Median age was 51 (22-82). Median PFS was 28.5 months, while median OS was 40.3 months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8 m vs. 28.5 m; p = 0.002) and OS (26.7 m vs. 40.3 m; p = 0.009). Patients older than 65 years of age (n: 42, 13.2%) had significantly lower OS results (19.8 m vs. 40.3 m; p = 0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.

Conclusions: Our RLP trial included only visceral metastatic, trastuzumab-naïve BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.

Keywords: AntiHER2; Brain metastasis; Pertuzumab; Trastuzumab; Visceral metastasis.

PubMed Disclaimer

MeSH terms

LinkOut - more resources